Dyne Therapeutics reports Q2 2026 net loss of $178.6M; BLA for z-rostudirsen accepted with Priority Review

Dyne Therapeutics, Inc.

2026-Q2 EPS reported -$1.81

Net loss of $178.6M ($1.08 per share) vs $110.9M ($0.97) in Q2 2025.
BLA for z-rostudirsen (exon 51 DMD) accepted by FDA with Priority Review; PDUFA date Jan 21, 2027.
Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for z-basivarsen in DM1; topline data Q1 2027.
IND cleared for DYNE-302 in FSHD; Phase 1 trial planned.
Cash, cash equivalents and marketable securities $898.5M as of June 30, 2026; expected cash runway into Q2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.